SCHEMBL1712628

SCHEMBL1712628

O=C(C1CCCN(S(=O)(=O)c2ccccc2Cl)C1)N1CCCC1c1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.51
POLB P06746 1/20 0.50
MAPT P10636 6/20 0.48
CNR1 P21554 1/20 0.48
KMT2A Q03164 5/20 0.47
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 2/20 0.46
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
CCR1 P32246 1/20 0.46
MAPK1 P28482 2/20 0.45
HSD11B1 P28845 1/20 0.45
USP2 O75604 1/20 0.44
PKM P14618 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1713030 0.92 CNR1 (0.56) FAAHPOLBMAPTCNR1KMT2A
SCHEMBL1722857 0.90 CNR1 (0.56) FAAHPOLBMAPTCNR1KMT2A
SCHEMBL1713229 0.88 POLB (0.55) POLBMAPTCNR1KMT2ALMNA
SCHEMBL1713307 0.87 POLB (0.56) POLBMAPTCNR1KMT2ALMNA
SCHEMBL1713125 0.85 POLB (0.53) FAAHPOLBMAPTCNR1KMT2A
SCHEMBL1713470 0.85 MAPT (0.66) MAPTKMT2ALMNASMN1; SMN2KDM4E
SCHEMBL1712996 0.83 POLB (0.50) FAAHPOLBMAPTCNR1KMT2A
SCHEMBL1713497 0.83 MAPT (0.64) MAPTKMT2ALMNASMN1; SMN2KDM4E
SCHEMBL13744221 0.83 POLB (0.47) FAAHPOLBMAPTCNR1KMT2A
SCHEMBL3428003 0.82 ATM (0.51) POLBMAPTKMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202888-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US claimed
EP-2252587-B1 PIPERIDINE SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-07-20 EP claimed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US claimed
US-8691846-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2014-04-08 US disclosed
US-8691846-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2014-04-08 US disclosed
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-22 US disclosed
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-22 US disclosed
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-22 US disclosed
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES KNUST HENNER (DE) 2012-09-20 US disclosed
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES KNUST HENNER (DE) 2012-09-20 US disclosed
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES KNUST HENNER (DE) 2012-09-20 US disclosed
US-8202888-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US disclosed
US-8202888-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US disclosed
US-8202888-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US disclosed
EP-2252587-B1 PIPERIDINE SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-07-20 EP disclosed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US disclosed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US disclosed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES HCRTR2, PER2, HCRTR1 FAAH 295/4885POLB 3190/4885MAPT 1778/4885
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES HCRTR2, PER2, HCRTR1 FAAH 295/4885POLB 3190/4885MAPT 1778/4885
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES HCRTR2, PER2, HCRTR1 FAAH 295/4885POLB 3190/4885MAPT 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.